Literature DB >> 32886157

Clinical Pharmacology of Botulinum Toxin Drugs.

Dirk Dressler1.   

Abstract

Botulinum toxin (BT) has changed from a deadly poison to a novel therapeutic principle for a large number of disorders in many medical areas.BT drugs are special in many ways: they are biologicals, their active ingredient BT is not patentable, their spectrum of clinical applications is extremely broad, their dose range is enormous, their mode of action is local and their life cycles are special.This review covers BT's therapeutic mode of action, time course of action, target tissues, pharmacological profile, adverse effects, interactions, potency labelling and antigenicity as well as BT's therapeutic preparations.

Keywords:  Adverse effects; Antigenicity; Botulinum toxin; Clinical pharmacology; Interactions; Mode of action; Pharmacological profile; Potency labelling; Target tissues; Therapeutic preparations; Time course

Year:  2021        PMID: 32886157     DOI: 10.1007/164_2019_273

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  44 in total

1.  Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.

Authors:  Dirk Dressler; Reiner Benecke
Journal:  Eur Neurol       Date:  2003       Impact factor: 1.710

Review 2.  Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.

Authors:  Dirk Dressler
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

3.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.

Authors:  H C Diener; D W Dodick; S K Aurora; C C Turkel; R E DeGryse; R B Lipton; S D Silberstein; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

4.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

5.  Safety of botulinum toxin short interval therapy using incobotulinumtoxin A.

Authors:  Dirk Dressler; Fereshte Adib Saberi
Journal:  J Neural Transm (Vienna)       Date:  2016-10-17       Impact factor: 3.575

6.  Botulinum toxin: dangerous terminology errors.

Authors:  M F Brin; A Blitzer
Journal:  J R Soc Med       Date:  1993-08       Impact factor: 5.344

7.  Subclinical myasthenia gravis causing increased sensitivity to botulinum toxin therapy.

Authors:  Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2010-10-16       Impact factor: 3.575

8.  Routine use of Xeomin in patients previously treated with Botox: long term results.

Authors:  D Dressler
Journal:  Eur J Neurol       Date:  2009-12       Impact factor: 6.089

9.  Long-distance retrograde effects of botulinum neurotoxin A.

Authors:  Flavia Antonucci; Chiara Rossi; Laura Gianfranceschi; Ornella Rossetto; Matteo Caleo
Journal:  J Neurosci       Date:  2008-04-02       Impact factor: 6.167

10.  Economics of botulinum toxin therapy: influence of the abobotulinumtoxinA package size on the costs of botulinum toxin therapy.

Authors:  Dirk Dressler; Fereshte Adib Saberi
Journal:  J Clin Mov Disord       Date:  2017-04-27
View more
  3 in total

Review 1.  Botulinum Toxin in Movement Disorders: An Update.

Authors:  Charenya Anandan; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2021-01-08       Impact factor: 4.546

Review 2.  Botulinum toxin therapy: past, present and future developments.

Authors:  Dirk Dressler; Eric A Johnson
Journal:  J Neural Transm (Vienna)       Date:  2022-04-09       Impact factor: 3.850

Review 3.  Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review.

Authors:  Dirk Dressler; Lizhen Pan; Junhui Su; Fei Teng; Lingjing Jin
Journal:  Toxins (Basel)       Date:  2021-05-22       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.